Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/63566
Type
ArticleCopyright
Restricted access
Embargo date
2025-12-31
Collections
Metadata
Show full item record
EVALUATION OF HUMORAL IMMUNE RESPONSE AFTER YELLOW FEVER INFECTION: AN OBSERVATIONAL STUDY ON PATIENTS FROM THE 2017-2018 SYLVATIC OUTBREAK IN BRAZIL
PRNT
YF immune response
late relapsing hepatitis after yellow fever
neutralizing antibodies; sylvatic YF
wild-type strain
yellow fever
Author
Gonçalves, Andreza Parreiras
Almeida, Letícia Trindade
Rezende, Izabela Maurício de
Fradico, Jordana Rodrigues Barbosa
Pereira, Leonardo Soares
Ramalho, Dario Brock
Xavier, Marcelo Antônio Pascoal
Silva, Carlos Eduardo Calzavara
Monath, Thomas P
LaBeaud, Angelle Desiree
Drumond, Betania Paiva
Campi-Azevedo, Ana Carolina
Martins Filho, Olindo Assis
Carvalho, Andréa Teixeira de
Alves, Pedro Augusto
Grupo de Estudos de Pesquisa e Resposta em Febre Amarela do Estado de Minas Gerais
Almeida, Letícia Trindade
Rezende, Izabela Maurício de
Fradico, Jordana Rodrigues Barbosa
Pereira, Leonardo Soares
Ramalho, Dario Brock
Xavier, Marcelo Antônio Pascoal
Silva, Carlos Eduardo Calzavara
Monath, Thomas P
LaBeaud, Angelle Desiree
Drumond, Betania Paiva
Campi-Azevedo, Ana Carolina
Martins Filho, Olindo Assis
Carvalho, Andréa Teixeira de
Alves, Pedro Augusto
Grupo de Estudos de Pesquisa e Resposta em Febre Amarela do Estado de Minas Gerais
Affilliation
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Department of Pediatrics. Infectious Disease Division. Stanford University School of Medicine. Stanford, CA, USA.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Microbiologia. Belo Horizonte, MG, Brazil/Estado de Minas Gerais. Fundação Hospitalar. Hospital Eduardo de Menezes. Belo Horizonte, MG, Brazil.
Estado de Minas Gerais. Fundação Hospitalar. Hospital Eduardo de Menezes. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil/Universidade Federal de Minas Gerais. Faculdade de Medicina. Departamento de Anatomia Patológica e Medicina Legal. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Crozet BioPharma LLC. Lexington, MA, USA.
Department of Pediatrics. Infectious Disease Division. Stanford University School of Medicine. Stanford, CA, USA.
Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Microbiologia. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
-----------------------
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Department of Pediatrics. Infectious Disease Division. Stanford University School of Medicine. Stanford, CA, USA.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Microbiologia. Belo Horizonte, MG, Brazil/Estado de Minas Gerais. Fundação Hospitalar. Hospital Eduardo de Menezes. Belo Horizonte, MG, Brazil.
Estado de Minas Gerais. Fundação Hospitalar. Hospital Eduardo de Menezes. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil/Universidade Federal de Minas Gerais. Faculdade de Medicina. Departamento de Anatomia Patológica e Medicina Legal. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Crozet BioPharma LLC. Lexington, MA, USA.
Department of Pediatrics. Infectious Disease Division. Stanford University School of Medicine. Stanford, CA, USA.
Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Microbiologia. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brazil.
-----------------------
Abstract
Between 2016 and 2018, Brazil experienced major sylvatic yellow fever (YF) outbreaks that caused hundreds of casualties, with Minas Gerais (MG) being the most affected state. These outbreaks provided a unique opportunity to assess the immune response triggered by the wild-type (WT) yellow fever virus (YFV) in humans. The plaque reduction neutralization test (PRNT) is currently the standard method to assess the humoral immune response to YFV by measuring neutralizing antibodies (nAbs). The present study aimed to evaluate the humoral immune response of patients from the 2017-2018 sylvatic YF outbreak in MG with different disease outcomes by using PRNTs with a WT YFV strain, isolated from the 2017-2018 outbreak, and a vaccine YFV strain. Samples from naturally infected YF patients were tested, in comparison with healthy vaccinees. Results showed that both groups presented different levels of nAb against the WT and vaccine strains, and the levels of neutralization against the strains varied homotypically and heterotypically. Results based on the geometric mean titers (GMTs) suggest that the humoral immune response after a natural infection of YFV can reach higher levels than that induced by vaccination (GMT of patients against WT YFV compared to GMT of vaccinees, P < 0.0001). These findings suggest that the humoral immune responses triggered by the vaccine and WT strains of YFV are different, possibly due to genetic and antigenic differences between these viruses. Therefore, current means of assessing the immune response in naturally infected YF individuals and immunological surveillance methods in areas with intense viral circulation may need to be updated.IMPORTANCEYellow fever is a deadly febrile disease caused by the YFV. Despite the existence of effective vaccines, this disease still represents a public health concern worldwide. Much is known about the immune response against the vaccine strains of the YFV, but recent studies have shown that it differs from that induced by WT strains. The extent of this difference and the mechanisms behind it are still unclear. Thus, studies aimed to better understand the immune response against this virus are relevant and necessary. The present study evaluated levels of neutralizing antibodies of yellow fever patients from recent outbreaks in Brazil, in comparison with healthy vaccinees, using plaque reduction neutralization tests with WT and vaccine YFV strains. Results showed that the humoral immune response in naturally infected patients was higher than that induced by vaccination, thus providing new insights into the immune response triggered against these viruses.
Keywords
17DD YFV strainPRNT
YF immune response
late relapsing hepatitis after yellow fever
neutralizing antibodies; sylvatic YF
wild-type strain
yellow fever
Share